Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: A review

General Pharmacology

Volumn 27, Issue 6, 1996, Pages 943-956

  Bondeson, Jan ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

interleukin 1; lipoxygenase; rheumatoid arthritis; tenidap; tumor necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; CYTOKINE; GLYCOSAMINOGLYCAN; INOSITOL PHOSPHATE; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE C; PROPIONIC ACID; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID; TENIDAP; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ACUTE PHASE RESPONSE; ARACHIDONIC ACID METABOLISM; CELL PH; CELL TYPE; CLINICAL TRIAL; DEGRANULATION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; MACROPHAGE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 0030250824     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-3623(95)02049-7     Document Type: Review

References (68)

1. 2 in vitro by mechanisms independent of inhibition of prostaglandin synthesis. Arthrit. Rheum. 34 (suppl. 9), S192.
2. Arend W. P. and Dayer J.-M. (1995) Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthrit. Rheum. 38, 151-160.
3. Avery M. J., Mitchell D. Y., Falkner F. C. and Fouda H. G. (1992) Simultaneous detection of tenidap and its stable isotype analog in serum by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. Biol. Mass Spect. 21, 353-357.
4. Blackburn W. D. Jr., Heck L. W., Loose L. D., Eskra J. D. and Carty T. J. (1991a) Inhihition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthrit. Rheum. 34, 204-210.
5. Blackburn W. D. Jr., Loose L. D., Heck L. W. and Chatham W. W. (1991b) Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase. Arthrit. Rheuma. 34, 211-216.
6. Blackburn W. D., Loose L. D. and Chatham W. W. (1993) Tenidap enhances basal chondrocyte proteoglycan synthesis and reverses IL-1 induced effects. Arthrit. Rheum. 36 (suppl. 9), S265.
7. Blackburn W. D., et al. (1995) Tenidap in rheumatoid arthritis: a 24-week double-blind comparison with hydroxychloroquine plus piroxicam and piroxicam alone. Arthrit. Rheum. 38, 1447-1456.
8. 2 and subsequent eicosanoid formation in macrophages. Biochem. Pharmac. 48, 1171-1179.
9. Bondeson J. and Sundler R. (1996) Auranofin inhibits the induction of interleukin-1β and tumor necrosis factor α mRNA in macrophages. Biochem. Pharmac. 50, 1753-1759.
10. Bondeson J. and Sundler R. (1996) Differential effects of tenidap on the zymosan-and lipopolysaccharide-induced expression of mRNA for proinflammatory cytokines in macrophages. Biochem Pharmac. 52, 35-42.
11. Bondeson J., Naucler C., Tapper H. and Sundler R. (1996) Does tenidap inhibit arachidonate release in macrophages through lowering intracellular pH? Manuscript.
12. Breedveld F. (1994) Tenidap: a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis. Scand. J. Rheumatol. 23 (suppl. 100), 31-44.
13. Carty T. J., Showell H. J., Loose L. D. and Kadin S. B. (1988) Inhibition of both 5-lipoxygenase (5-LO) and cyclooxygenase (CO) pathways of arachidonic acid (AA) metabolism by CP-66, 248. Arthrit. Rheum. 31 (suppl. 4), S89.
14. Chatham W. W., Hansen T., Loose L. and Blackburn W. D. (1994) Effects of tenidap on superoxide generating enzymes - non-competitive inhibition of xanthine oxidase. Arthrit. Rheum. 37 (suppl. 9), R27.
15. Cleveland P. L., Millard P. J., Showell H. J. and Fewtrell C. M. S. (1993) Tenidap: a novel inhibitor of calcium influx in a mast cell line. Cell Calcium 14, 1-16.
16. Conklyn M. J., Kadin S. B. and Showell H. J. (1990) Inhibition of IgE-mediated N-acetylglucosaminidase and serotonin release from rat basophilic leukemia cells (RBL-2H3) by tenidap: a novel anti-inflammatory agent. Int. Arch. Allerg. Appl. Immunol. 91, 369-373.
17. Dingle J. T., Leeming M. R. G. and Martindale J. J. (1993) Effect of tenidap on cartilage integrity in vitro. Ann. Rheum. Dis. 52, 292-299.
18. Duff G. W. (1994) Cytokines and acute phase proteins in rheumatoid arthritis. Scand. J. Rheumatol. 23, (suppl. 100), 9-19.
19. Feldmann M., Brennan F. M. and Maini R. N. (1996) Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14, 397-440..
20. 2 formation by exogenous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils. Arch. Dermatol. Res. 280, 430-436.
21. Genant H. K., Kirby D. S., Pickering E. A., Loose L. D., Werner E. S., Ting N. (1995) Tenidap slows x-ray deterioration in rheumatoid arthritis. Arthrit. Rheum. 38 (Suppl. 9). S330.
22. Golding S., Emery B. and Young S. P. (1995) Tenidap-modulated proinflammatory cytokine activation of a monocyte cell line. J. Immunol. 154, 5384-5390.
23. Griswold D. E., Hillegass L. M., Breton J. J., Esser K. M. and Adams J. L. (1993) Differentiation in vivo of classical non-steroidal antiinflammatory drugs from cytokine suppressive antiinflammatory drugs and other pharmacological classes using mouse tumour necrosis factor alpha production. Drugs Exp. Clin. Res. 19, 243-248.
24. Hartman D. A., Ochalski S. J. and Carlson R. P. (1993) The effects of antiinflammatory and antiiallergic drugs on the release ot IL-1beta and TNF-alpha in ihe human whole blood assay. Agents Action 39, C70-C72.
25. Kankaanranta H. and Moilanen E. (1995) Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes. Mol. Pharmac. 47, 1006-1013.
26. 2 on leukotriene and histamine release from human and guinea-pig lung. Prostaglandins 30, 199-208.
27. Kyan-Aung U., Lee T. H. and Haskard D. O. (1993) The inhibitory effect of tenidap on leukocyte-endothelial cell adhesion. J. Rheumatol. 20, 1014-1019.
28. Laliberte R., Perregaux D., Svensson L., Pazoles C. J. and Gabel C. A. (1994) Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. II. Inhibition of IL-1β production from ATP-treated monocytes and macrophages. J. Immunol. 153, 2168-2179.
29. Lau C. S. and Belch J. J. F. (1992) The in vitro free radical scavenging effect of tenidap, a new dual cyclo-oxygenase and 5-lipoxygenase inhibitor. Mediat. Inflamm. 1, 141-143.
30. Leeming M. R. G. (1993) A double-blind randomized comparison of tenidap versus auranofin plus diclofenac in early rheumatoid arthritis (RA). Arthrit. Rheum. 36 (suppl. 9), S111.
31. Lindsley H. B., Smith D. D. and Cohick C. B. (1993) Suppression by tenidap of IFNg-induced expression of HLA Class II antigen on cultured human synoviocytes (HSC), and reduction of PMBC adhesion to rheumatoid HSC in vitro. J. Immunol. 150 (suppl. II), 140A.
32. Littman B. H., Drury C. E., Bjarnason D., Bryant G., Engelbrecht J., Cohen M., Mertz L., Weaver A. and Hunder G. G. (1994a) Steroid sparing effect of tenidap in polymyalgia rheumatica. Arthrit. Rheum. 37 (suppl. 9), S354.
33. Littman B. H., Drury C. E., Schumacher R., Boyle D., Weisman M. and Firestein G. (1994b) In vivo reduction of RA synovial metalloproteinase mRNA levels by tenidap. Arthrit. Rheum. 37 (suppl. 9), S420.
34. Littman B. H., Drury C. E., Zimmerer R. O., Stack C. B. and Law C. G. (1995) Rheumatoid arthritis treated with tenidap and piroxicam. Clinical association with cytokine modulation by tenidap. Arthrit. Rheum. 38, 29-37.
35. Loose L. D., Wilhelm F. E., Kraska A. R., Kirby D. S., Ting N., Shanahan W. R. and Weiner E. S. (1993a) Double-blind, placebo-controlled, dose response study of tenidap in rheumatoid arthritis. Arthrit. Rheum. 36 (suppl. 9), S166.
36. Loose L. D., de Oliveira R., Sipe J. D., Franzblau C. and Shanahan W. R. (1993b) A possible systemic component of osteoarthritis (OA): elevated concentrations (by ELISA) of C-reactive protein (CRP) in serum of OA patients and modulation by tenidap. Arthrit. Rheum. 36 (suppl. 9), S166.
37. Loose L. D., Sipe J. D., Kirby D. S., Kraska A. R., Weiner E. S., Shanahan W. R., Leeming M. R. G., Farrow P., Stack C. B. and Ting N. (1993c) Reduction of acute-phase proteins with tenidap sodium, a cytokine-modulating anti-rheumatic drug. Br. J. Rheumatol. 32, 19-25.
38. Loose L. D., Weiner E. S., Kirby D. S., Wilhelm F. E. and Shanahan W.R. (1996) Tenidap vs naproxen vs placebo in rheumatoid arthritis (RA): a 2-week study in patients wih knee effusions. Arthrit. Rheum., (in press).
39. McDonald B., Loose L. and Rosenwasser L. J. (1988) The influence of a novel arachidonate inhibitor, CP66.248, on the production and activity of human monocyte IL-1. Arthrit. Rheum. 31 (suppl. 4), S17.
40. McNiff P., Svensson L., Pazoles C. J. and Gabel C. A. (1994) Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanism and evidence of functional significance. J. Immunol. 153, 2180-2193.
41. McNiff P., Laliberte R. E., Svensson L., Pazoles C. J. and Gabel C. A. (1995) Inhibition of cytokine activation processes in vitro by tenidap, a novel anti-inflammatory agent. Cytokine 7, 196-208.
42. 2. J. Rheumatol. 18, 59-65.
43. Martel-Pelletier J., Ounissi H., Cloutier J.-M., Pelletier J.-P. (1994) Tenidap effectively reduces cytokine synthesis and expression by human rheumatoid arthritis synovium. Arthrit. Rheum. 37 (suppl. 9), S309.
44. Mattey D. L., Evans E. and Dawes P. T. (1994) The effects of tenidap on cytokine induced proliferation of human synovial fibroblasfs in vitro. Ann. Rheum. Dis. 53, 250-255.
45. Moilanen E., Alanko J., Asmawi M. Z. and Vapaaralo H. (1988) Cp-66,248, a new antiinflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid syntheses in human polymorphonuclear leucocytes in vitro. Eicosanoids 1, 35-39.
46. Ochalski S. J., Hartman D. A., Belfast M. T., Walter T. L., Glaser K. B. and Carlson R. P. (1993) Inhibition of endotoxin-induced hypothermia and serum TNF-α levels in CD-1 mice by various pharmacological agents. Agents Actions 39 (special conference issue), C52-C54.
47. Olivers D. L., Laydon J. T., Hillegass L., Badger A. M. and Lee J. C. (1993) Effects of pyridinyl imidazole compounds on murine TNF-α production. Agents Actions 39 (special conference issue), C55-C57.
48. Otterness I. G., Carty T. J. and Loose L. D. (1989) Tenidap: a new drug for arthritis. In Therapeutic Approaches to Inflammatory Diseases (Edited by A. J. Lewis, N. S. Doherty, and N. R. Ackerman), New York. pp. 229-241.
49. Otterness I. G., Bliven M. L., Downs J. T., Natoli E. J. and Hanson D.C. (1991a) Inhibition of interleukin-1 synthesis by tenidap: a new drug for arthritis. Cytokine 3, 277-283.
50. Otterness I. G., Pazoles P. P., Moore P. F. and Pepys M. B. (1991b) C-reactive protein as an index of disease activity. Comparison of tenidap, cyclophosphamide and dexamethasone in rat adjuvant arthritis. J. Rheumatol. 18, 505-511.
51. Panes J., Russell J. M., Wolf R. E., Wallace J. L. and Granger D. N. (1995) Effects of tenidap on leukocyte-endothelial cell adhesion in mesenteric venules. J. Rheumatol. 22, 444-449.
52. Parkar B. A., McCormick M. E. and Foster S. J. (1990) Leukotrienes do not regulate interleukin-1 production by activated macrophages. Biochem. Biophys. Res. Commun. 169, 422-429.
53. Pelletier J.-P., McCollum R., DiBattista J., Loose L.D., Cloutier J.-M. and Martel-Pelletier J. (1993) Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthrit. Rheum. 36, 1517-1527.
54. Pelletier J.-P., Fernandes J., Mineau F., Otterness I. and Martel-Pelletier J. (1994) Tenidap markedly reduces the progression of lesions in experimental osteoarthritis: inhibition of metalloproteinase synthesis. Clin. Rheumatol. 13, 352.
55. Proudman K. E., McMillan R. M. (1991) Are tolfenamic acid and tenidap dual inhibitors of 5-lipoxygenase and cyclo-oxygenase? Agents Actions 34, 121-124.
56. Pruimboom W. M., van Dijk A. A. P. M., Tak C. J. A. M., Garrelds I., Bonta I. L., Wilson P. J. S. and Zijlstra F. J. (1994) Interactions between cytokines and eicosanoids: a study using human peritoneal macrophages. Immunol. Lett. 41, 255-260.
57. 2 synthesis by fetal rat calvarial osteoblasts. Mediat. Inflamm. 4, 67-70.
58. Rainford K. D., Ying C. and Smith F. (1993) Selective effects of some 5-lipoxygenase inhibitors on synovial interleukin-1 (IL-1) production compared with IL-1 synthesis inhibitors. Agents Actions 39 (special conference issue), C186-C188.
59. Rao A. (1995) NFATp, a cyclosporin-sensitive transcription factor implicated in cytokine gene induction. J. Leukoc. Biol. 57, 536-542.
60. Reinsprecht M., Rohn M. H., Spadinger R. J., Pecht L., Schindlet H. and Romanin C. (1995) Blockade of capacitive Ca2+ influx by Cl-channel blockers inhibits secretion from a rat mucosal-type mast cells. Mol Pharmac. 47, 1014-1020.
61. Remvig L., Enk C. and Bligaard N. (1988) Effect of auranofin and sodium aurothiomalate on interleukin-1 production from human monocytes in vivo. Scand. J. Rheumatol. 17, 255-262.
62. Russell A. S., Wilner K. D., Hansen R. A. (1994) Lack of a significant interaction between tenidap and low-dose oral methotrexate in rheumatoid arthritis (RA). arthrit. Rheum. 37 (suppl. 9), S336.
63. Sharif M., Meadows K. and Dieppe P. A. (1994) The effects of a 3-substituted 2-oxindole (tenidap) on a serum marker of cartilage degradation in osteoarthritis. Arthrit. Rheum. 37 (suppl. 9), S345.
64. Sipe J. D., Bartle L. M. and Loose L. D. (1992) Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. J. Immunol. 148, 480-484.
65. Smith D. M., Johnson J. A., Loeser R. and Turner R.A. (1990) Evaluation of tenidap (Cp 66248) on human neutrophil arachidonic acid metabolism, chemotactic potential and clinical efficacy in the treatment of rheumatoid arthritis. Agents Actions 31, 102-109.
66. Wilhelm F. E., Kirby D. S., Kraska A. R., Loose L. D., Shanahan W. R. Jr., Ting N. and Weiner E. S. (1994) Tenidap (ten) vs. piroxicam (pir) vs. piroxicam plus hydroxychloroquine (pir/hcq) in rheumatoid arthritis (RA). Results of a two-year trial. Arthrit. Rheum. 37 (suppl. 9), S336.
67. Wolf R. E., Baethge B. A. and Loose L. D. (1991) Differential effects of tenidap and naproxen on serum soluble interleukin-2 receptor (sIL-2R) levels in rheumatoid arthritis. Arthrit. Rheum. 34 (suppl. 5), R12.
68. Zhu X., Ertel W., Ayala A., Morrison M. H., Perrin M. M. and Chaudry I. H. (1993) Chloroquine inhibits macrophage tumour necrosis factot-α mRNA transcription. Immunology 80, 122-126.